Allergen immunotherapy and biologics in respiratory allergy: friends or foes?
Allergens
/ administration & dosage
Asthma
/ diagnosis
Biological Products
/ administration & dosage
Combined Modality Therapy
/ adverse effects
Desensitization, Immunologic
/ adverse effects
Glucocorticoids
/ administration & dosage
Humans
Rhinitis, Allergic
/ diagnosis
Severity of Illness Index
Treatment Outcome
Journal
Current opinion in allergy and clinical immunology
ISSN: 1473-6322
Titre abrégé: Curr Opin Allergy Clin Immunol
Pays: United States
ID NLM: 100936359
Informations de publication
Date de publication:
01 02 2021
01 02 2021
Historique:
entrez:
28
12
2020
pubmed:
29
12
2020
medline:
29
10
2021
Statut:
ppublish
Résumé
Allergen-specific immunotherapy has established as an indispensable disease-modifying treatment in allergy practice but its safety and efficacy might be furtherly improved by combining it with other drugs or therapeutic intervention that co-modulate immune type 2 immune networks. In the past two decades, clinical research focused on AIT and omalizumab co-treatment to improve both safety and long-term efficacy of allergic disease treatment. Recently, combination of AIT with other biologicals targeting different mediators of type 2 inflammation has been set up with interesting preliminary results. Moreover, AIT current contraindication might be overcome by contemporarily controlling underlying type 2 inflammation in severe atopic patients. AIT--biological combination treatment can realize a complex multitargeted treatment strategy allowing for consistently improving disease control and sparing steroid administration.
Identifiants
pubmed: 33369567
doi: 10.1097/ACI.0000000000000707
pii: 00130832-202102000-00004
doi:
Substances chimiques
Allergens
0
Biological Products
0
Glucocorticoids
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
16-23Informations de copyright
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.
Références
Casale TB, Stokes JR. Future forms of immunotherapy. J Allergy Clin Immunol 2011; 127:8–15.
Noon L. Prophylactic inoculation against hay fever. Lancet 1911; 1:1572.
Freeman J. Further observations on the treatment of hay fever by hypodermic inoculations of pollen vaccine. Lancet 1911; 2:814–817.
Li Y, Yu SY, Tang R, et al. Sublingual immunotherapy tablets relieve symptoms in adults with allergic rhinitis: a meta-analysis of randomized clinical trials. Chin Med J (Engl) 2018; 131:2583–2588.
Demoly P, Makatsori M, Casale TB, Calderon MA. The potential role of allergen immunotherapy in stepping down asthma treatment. J Allergy Clin Immunol Pract 2017; 5:640–648.
Fortescue R, Kew KM, Leung MST. Sublingual immunotherapy for asthma. Cochrane Database Syst Rev 2020; 9:CD011293.
Des Roches A, Paradis L, Menardo JL, et al. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children. J Allergy Clin Immunol 1997; 99:450–453.
Moller C, Dreborg S, Ferdousi HA, et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol 2002; 109:251–256.
Kucuksezer UC, Ozdemir C, Cevhertas L, et al. Mechanisms of allergen-specific immunotherapy and allergen tolerance. Allergol Int 2020; 69:549–560.
Heffler E, Paoletti G, Giorgis V, et al. Real-life studies of biologics used in asthma patients: key differences and similarities to trials. Expert Rev Clin Immunol 2019; 15:951–958.
McGregor MC, Krings JG, Nair P, Castro M. Role of biologics in asthma. Am J Respir Crit Care Med 2019; 199:433–445.
Adachi M, Kozawa M, Yoshisue H, et al. Real-world safety and efficacy of omalizumab in patients with severe allergic asthma: a long-term postmarketing study in Japan. Respir Med 2018; 141:56–63.
Campo P, Soto Campos G, Aparicio MB, et al. Severe asthma phenotypes in patients controlled with omalizumab: a real-world study. Respir Med 2019; 159:105804.
Canonica GW, Rottoli P, Bucca C, et al. PROXIMA study centers. Improvement of patient-reported outcomes in severe allergic asthma by omalizumab treatment: the real life observational PROXIMA study. World Allergy Organ J 2018; 11:33.
Humbert M, Taillé C, Mala L, et al. STELLAIR investigators. Omalizumab effectiveness in patients with severe allergic asthma according to blood eosinophil count: the STELLAIR study. Eur Respir J 2018; 51:1702523.
Adelroth E, Rak S, Haahtela T, et al. Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. J Allergy Clin Immunol 2000; 106:253–259.
Okubo K, Ogino S, Nagakura T, Ishikawa T. Omalizumab is effective and safe in the treatment of Japanese cedar pollen-induced seasonal allergic rhinitis. Allergol Int 2006; 55:379–386.
Nagakura T, Ogino S, Okubo K, et al. Omalizumab is more effective than suplatast tosilate in the treatment of Japanese cedar pollen-induced seasonal allergic rhinitis. Clin Exp Allergy 2008; 38:329–337.
Penn R, Mikula S. The role of anti-IgE immunoglobulin therapy in nasal polyposis: a pilot study. Am J Rhinol 2007; 21:428–432.
Gevaert P, Calus L, Van Zele T, et al. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J Allergy Clin Immunol 2013; 131:110.e1–116.e1.
Tsabouri S, Tseretopoulou X, Priftis K, Ntzani EE. Omalizumab for the treatment of inadequately controlled allergic rhinitis: a systematic review and meta-analysis of randomized clinical trials. J Allergy Clin Immunol Pract 2014; 2:332.e1–340.e1.
Bayar Muluk N, Bafaqeeh SA, Cingi C. Anti-IgE treatment in allergic rhinitis. Int J Pediatr Otorhinolaryngol 2019; 127:109674.
Pelaia C, Paoletti G, Puggioni F, et al. Interleukin-5 in the pathophysiology of severe asthma. Front Physiol 2019; 10:1514.
Brusselle GG, Maes T, Bracke KR. Eosinophils in the spotlight: eosinophilic airway inflammation in nonallergic asthma. Nat Med 2013; 19:977–979.
Agache I, Song Y, Rocha C, et al. Efficacy and safety of treatment with dupilumab for severe asthma: a systematic review of the EAACI guidelines-recommendations on the use of biologicals in severe asthma. Allergy 2020; 75:1058–1068.
Normansell R, Walker S, Milan SJ, et al. Omalizumab for asthma in adults and children. Cochrane Database Syst Rev 2014; (1):CD003559.
Farne HA, Wilson A, Powell C, et al. Anti-IL5 therapies for asthma. Cochrane Database Syst Rev 2017; 9:CD010834.
Xiong XF, Zhu M, Wu HX, et al. Efficacy and safety of dupilumab for the treatment of uncontrolled asthma: a meta-analysis of randomized clinical trials. Respir Res 2019; 20:108.
Porsbjerg CM, Sverrild A, Lloyd CM, et al. Antialarmins in asthma: targeting the airway epithelium with next-generation biologics. Eur Respir J 2020; 56:2000260.
Pitsios C, Demoly P, Bilò MB, et al. Clinical contraindications to allergen immunotherapy: an EAACI position paper. Allergy 2015; 70:897–909.
Incorvaia C, Al-Ahmad M, Ansotegui IJ, et al. Personalized medicine for allergy treatment: allergen immunotherapy still a unique and unmatched model. Allergy 2020; 14575[Epub ahead of print].
Epstein TG, Liss GM, Berendts KM, Bernstein DI. AAAAI/ACAAI Subcutaneous Immunotherapy Surveillance Study (2013-2017): fatalities, infections, delayed reactions, and use of epinephrine autoinjectors. J Allergy Clin Immunol Pract 2019; 7:1996.e1–2003.e1.
Bernstein DI, Wanner M, Borish L, Liss GM. Immunotherapy Committee, American Academy of Allergy, Asthma and Immunology. Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990-2001. J Allergy Clin Immunol 2004; 113:1129–1136.
Piconi S, Trabattoni D, Saresella M, et al. Effects of specific immunotherapy on the B7 family of costimulatory molecules in allergic inflammation. J Immunol 2007; 178:1931–1937.
Riccio AM, Saverino D, Pesce G, et al. Effects of different up-dosing regimens for hymenoptera venom immunotherapy on serum CTLA-4 and IL-10. PLoS One 2012; 7:e37980.
Durham SR, Walker SM, Varga EM, et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999; 341:468–475.
Deurloo DT, van Oosterhout AJ. Role of T cell co-stimulation in murine models of allergic asthma. Clin Exp Allergy 2004; 34:17–25.
Kopp MV. Role of immunmodulators in allergen-specific immunotherapy. Allergy 2011; 66:792–797.
Maazi H, Shirinbak S, den Boef LE, et al. Cytotoxic T lymphocyte antigen 4-immunoglobulin G is a potent adjuvant for experimental allergen immunotherapy. Clin Exp Immunol 2013; 172:113–120.
Aguilar-Pimentel A, Graessel A, Alessandrini F, et al. Improved efficacy of allergen-specific immunotherapy by JAK inhibition in a murine model of allergic asthma. PLoS One 2017; 12:e0178563.
Russkamp D, Aguilar-Pimentel A, Alessandrini F, et al. IL-4 receptor α blockade prevents sensitization and alters acute and long-lasting effects of allergen-specific immunotherapy of murine allergic asthma. Allergy 2019; 74:1549–1560.
Braido F, Corsico A, Rogkakou A, et al. The relationship between allergen immunotherapy and omalizumab for treating asthma. Expert Rev Respir Med 2015; 9:129–134.
Dantzer JA, Wood RA. The use of omalizumab in allergen immunotherapy. Clin Exp Allergy 2018; 48:232–240.
Kuehr J, Brauburger J, Zielen S, et al. Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J Allergy Clin Immunol 2002; 109:274–280.
Rolinck-Werninghaus C, Hamelmann E, Keil T, et al. Omalizumab Rhinitis Study Group. The co-seasonal application of anti-IgE after preseasonal specific immunotherapy decreases ocular and nasal symptom scores and rescue medication use in grass pollen allergic children. Allergy 2004; 59:973–979.
Kopp MV, Hamelmann E, Zielen S, et al. DUAL study group. Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma. Clin Exp Allergy 2009; 39:271–279.
Larenas-Linnemann D, Wahn U, Kopp M. Use of omalizumab to improve desensitization safety in allergen immunotherapy. J Allergy Clin Immunol 2014; 133:937.e2–937.e2.
Casale TB, Busse WW, Kline JN, et al. Immune Tolerance Network Group. Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol 2006; 117:134–140.
Klunker S, Saggar LR, Seyfert-Margolis V, et al. Immune Tolerance Network Group. Combination treatment with omalizumab and rush immunotherapy for ragweed-induced allergic rhinitis: Inhibition of IgE-facilitated allergen binding. J Allergy Clin Immunol 2007; 120:688–695.
Massanari M, Nelson H, Casale T, et al. Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma. J Allergy Clin Immunol 2010; 125:383–389.
Lambert N, Guiddir T, Amat F, Just J. Pretreatment by omalizumab allows allergen immunotherapy in children and young adults with severe allergic asthma. Pediatr Allergy Immunol 2014; 25:829–832.
Stelmach I, Majak P, Jerzyńska J, et al. Children with severe asthma can start allergen immunotherapy after controlling asthma with omalizumab: a case series from Poland. Arch Med Sci 2015; 11:901–904.
Zöllner EW, Lombard CJ, Galal U, et al. Hypothalamic-pituitary-adrenal axis suppression in asthmatic school children. Pediatrics 2012; 130:e1512–e1519.
Heffler E, Madeira LNG, Ferrando M, et al. Inhaled corticosteroids safety and adverse effects in patients with asthma. J Allergy Clin Immunol Pract 2018; 6:776–781.
Forbush JT, Banks TA. Omalizumab and allergen immunotherapy in a patient with asthma and inhaled corticosteroid-induced adrenal suppression. Ann Allergy Asthma Immunol 2016; 117:335–337.
Stock P, Rolinck-Werninghaus C, Wahn U, Hamelmann E. The role of anti-IgE therapy in combination with allergen specific immunotherapy for seasonal allergic rhinitis. BioDrugs 2007; 21:403–410.
Amat F, Tallon P, Foray AP, et al. Control of asthma by omalizumab: the role of CD4+ Foxp3+ regulatory T cells. Clin Exp Allergy 2016; 46:1614–1616.
Kopp MV, Hamelmann E, Bendiks M, et al. DUAL study group. Transient impact of omalizumab in pollen allergic patients undergoing specific immunotherapy. Pediatr Allergy Immunol 2013; 24:427–433.
Chaker AM, Shamji MH, Dumitru FA, et al. Short-term subcutaneous grass pollen immunotherapy under the umbrella of anti-IL-4: a randomized controlled trial. J Allergy Clin Immunol 2016; 137:452.e9–461.e9.
Gülsen A, Wallis S, Jappe U. Combination of immunotherapies for severe allergic asthma. J Asthma 2019; 1–4. doi: 10.1080/02770903.2019.1658204 [Epub ahead of print].
doi: 10.1080/02770903.2019.1658204
Moscato G, Pala G, Sastre J. Specific immunotherapy and biological treatments for occupational allergy. Curr Opin Allergy Clin Immunol 2014; 14:576–581.
Egan M, Atkins D. What is the relationship between eosinophilic esophagitis (EoE) and aeroallergens? Implications for Allergen Immunotherapy. Curr Allergy Asthma Rep 2018; 18:43.
Helou DG, Shafiei-Jahani P, Lo R, et al. PD-1 pathway regulates ILC2 metabolism and PD-1 agonist treatment ameliorates airway hyperreactivity. Nat Commun 2020; 11:3998.